新冠疫情期间炎症性肠病的治疗挑战：一种观点
The Challenges in Treating Inflammatory Bowel Diseases During the COVID-19 Pandemic: An Opinion.
作者信息
Vukovic Jonatan, Jukic Ivana, Tonkic Ante
机构信息
Department of Gastroenterology and Hepatology, Internal Clinic, Clinical Hospital Centre Split, Spinciceva 1, 21000 Split, Croatia.
Department of Internal Medicine, School of Medicine, University of Split, 21000 Split, Croatia.
出版信息
J Clin Med. 2024 Nov 25;13(23):7128. doi: 10.3390/jcm13237128.
Abstract
The COVID-19 pandemic posed significant challenges in the treatment of chronic diseases, particularly inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis. These challenges are multifaceted, encompassing difficulties in maintaining routine care, concerns about the safety of immunosuppressive therapies, disruptions in healthcare delivery, and the complexities of managing IBD in patients who contract COVID-19. This article explores the various obstacles faced in the treatment of IBD during the pandemic and discusses potential strategies to overcome these challenges.
摘要
新冠疫情给慢性病治疗带来了重大挑战，尤其是炎症性肠病（IBD），如克罗恩病和溃疡性结肠炎。这些挑战是多方面的，包括维持常规治疗的困难、对免疫抑制疗法安全性的担忧、医疗服务的中断，以及管理感染新冠病毒的炎症性肠病患者的复杂性。本文探讨了疫情期间炎症性肠病治疗面临的各种障碍，并讨论了克服这些挑战的潜在策略。
相似文献
1
The Challenges in Treating Inflammatory Bowel Diseases During the COVID-19 Pandemic: An Opinion.新冠疫情期间炎症性肠病的治疗挑战：一种观点
J Clin Med. 2024 Nov 25;13(23):7128. doi: 10.3390/jcm13237128.
2
Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?炎症性肠病患者的新型冠状病毒2型疫苗接种：我们目前的情况如何？
Life (Basel). 2021 Nov 11;11(11):1220. doi: 10.3390/life11111220.
3
Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary.加拿大克罗恩病与结肠炎协会《2021年新冠疫情对加拿大炎症性肠病的影响：执行摘要》
J Can Assoc Gastroenterol. 2021 Nov 5;4(Suppl 2):S1-S9. doi: 10.1093/jcag/gwab027. eCollection 2021 Dec.
4
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.临床实践新进展：COVID-19 大流行期间炎症性肠病的管理。
Gut. 2022 Jul;71(7):1426-1439. doi: 10.1136/gutjnl-2021-326784. Epub 2022 Apr 27.
5
Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic.接受免疫抑制药物治疗的炎症性肠病患者：大流行期间对 COVID-19 及医疗服务的看法。
Scand J Gastroenterol. 2021 May;56(5):545-551. doi: 10.1080/00365521.2021.1901308. Epub 2021 Mar 26.
6
Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview.炎症性肠病：临床诊断与外科治疗概述。
Medicina (Kaunas). 2022 Apr 21;58(5):567. doi: 10.3390/medicina58050567.
7
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.通过RAND方法评估炎症性肠病中免疫抑制药物的适用性：意大利炎症性肠病研究小组（IG-IBD）立场声明
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
8
Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study.维多珠单抗用于儿童炎症性肠病的维持治疗（VEDOKIDS）：一项多中心、前瞻性队列研究的54周结果
Lancet Gastroenterol Hepatol. 2025 Mar;10(3):234-247. doi: 10.1016/S2468-1253(24)00319-4. Epub 2025 Jan 6.
9
Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.炎症性肠病患者感染 SARS-CoV-2 及对 COVID-19 疫苗免疫应答的风险：当前证据。
Front Immunol. 2022 Jun 23;13:933774. doi: 10.3389/fimmu.2022.933774. eCollection 2022.
10
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.2018年炎症性肠病对加拿大的影响：直接成本与医疗服务利用情况
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.
引用本文的文献
1
Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.靶向内源性大麻素系统：一种治疗炎症性肠病肠外并发症的新方法。
Pharmaceuticals (Basel). 2025 Mar 27;18(4):478. doi: 10.3390/ph18040478.
本文引用的文献
1
Global burden of inflammatory bowel disease in the elderly: trends from 1990 to 2021 and projections to 2051.老年人炎症性肠病的全球负担：1990年至2021年的趋势及2051年的预测
Front Aging. 2024 Oct 24;5:1479928. doi: 10.3389/fragi.2024.1479928. eCollection 2024.
2
The trends and outcomes of inflammatory bowel disease surgery during the COVID-19 pandemic: A retrospective propensity score-matched analysis from a multi-institutional research network.2019冠状病毒病大流行期间炎症性肠病手术的趋势与结果：一项来自多机构研究网络的回顾性倾向评分匹配分析
Health Sci Rep. 2024 Sep 29;7(10):e70107. doi: 10.1002/hsr2.70107. eCollection 2024 Oct.
3
Comprehensive analysis to identify the influences of SARS-CoV-2 infections to inflammatory bowel disease.全面分析识别 SARS-CoV-2 感染对炎症性肠病的影响。
Front Immunol. 2023 Feb 3;14:1024041. doi: 10.3389/fimmu.2023.1024041. eCollection 2023.
4
The Effects of the COVID Pandemic on Patients with IBD: Lessons Learned and Future Directions.新冠疫情对炎症性肠病患者的影响：经验教训与未来方向
J Clin Med. 2022 Nov 27;11(23):7002. doi: 10.3390/jcm11237002.
5
COVID-19 infection: an overview on cytokine storm and related interventions.COVID-19 感染：细胞因子风暴及相关干预措施概述。
Virol J. 2022 May 26;19(1):92. doi: 10.1186/s12985-022-01814-1.
6
COVID-19 Vaccination in Inflammatory Bowel Disease (IBD).炎症性肠病（IBD）中的COVID-19疫苗接种
J Clin Med. 2022 May 9;11(9):2676. doi: 10.3390/jcm11092676.
7
Impact of COVID-19 pandemic on the healthcare and psychosocial well-being of patients with inflammatory bowel disease.2019年冠状病毒病大流行对炎症性肠病患者医疗保健及心理社会福祉的影响
Ann Gastroenterol. 2022 Mar-Apr;35(2):103-112. doi: 10.20524/aog.2022.0686. Epub 2022 Feb 10.
8
Impact of COVID-19 on Healthcare Resource Utilisation Among Patients with Inflammatory Bowel Disease in the USA.COVID-19 对美国炎症性肠病患者医疗资源利用的影响。
J Crohns Colitis. 2022 Sep 8;16(9):1405-1414. doi: 10.1093/ecco-jcc/jjac056.
9
COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.COVID-19 与炎症性肠病患者的结局：系统评价和荟萃分析。
Inflamm Bowel Dis. 2022 Aug 1;28(8):1265-1279. doi: 10.1093/ibd/izab236.
10
Assessing the indirect effects of COVID-19 on healthcare delivery, utilization and health outcomes: a scoping review.评估 COVID-19 对医疗服务提供、利用和健康结果的间接影响：范围综述。
Eur J Public Health. 2021 Jul 13;31(3):634-640. doi: 10.1093/eurpub/ckab047.
Zotero 插件